/
Insulet Corporation ( we or the Company ) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod 5 Automated Insulin Delivery System ( Omnipod 5 ), the Omnipod DASH Insulin Management System ( Omnipod DASH ), and the Omnipod Insulin Management Sys…
17.50% operating margin is respectable but not wide. ROIC at 14.69%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 30.7% YoY with margins expanding 2.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$2.90B
▲ +30.7% YoY
Net Income (TTM)
$303M
▼ -40.9% YoY
Op. Margin
17.51%
▲ +2.6pp YoY
ROIC
16.17%
▲ +4.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$416M
▲ +23.7% YoY
Op. Cash Flow (TTM)
$619M
▲ +32.3% YoY
Net Debt
$471M
Cash & Equiv.
$480M
5Y CAGR: +24.5%
Continue Research